CervoMed Inc (CRVO) USD0.001
Sell:$6.11Buy:$6.88
$1.06
(14.85%)
- This stock can be held in a
Stocks and Shares ISA$1.06
(14.85%)$1.06
(14.85%)Company Information
About this company
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Key people
Key facts
- EPICCRVO
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS15713L1098
- Market cap$59.35m
- Employees15
- Shares in issue8.70m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.